



**ARGONAUT**  
The Natural Choice in Resources

# EQUITY RESEARCH

Financial Advisers | Stockbroking & Research | Special Situations Financing

www.argonaut.com +61 8 9224 6888

## BUY

Current Price \$0.72

Valuation \$1.08

Ticker: **SRG.ASX**  
Sector: **Services & Construction**

Shares on Issue (m): **519.5**  
Market Cap (\$m): **374.0**  
Net Debt / (Cash) (\$m): **17.0**  
Enterprise Value (\$m): **391.0**

52 wk High/Low: **0.81 0.66**  
12m Av Daily Vol (m): **0.56**

### Key Metrics

	24F	25F
EV/EBITDA (x)	4.1	3.8
EV/EBIT (x)	6.4	5.9
P/E (x)	9.2	8.1

### Ratios

	23A	24F	25F
ND / Equity	5.8%	-0.5%	-5.8%
EBIT Mgn	6.2%	6.2%	6.5%
RoA	10.3%	11.0%	11.7%
RoE	12.1%	13.8%	15.0%

### Financials\*:

	23A	24F	25F
Revenue (\$m)	811.6	980.0	1,030.1
EBITDA (\$m)	80.1	96.1	101.9
EBIT (\$m)	50.0	61.0	66.6
NPAT (\$m)	31.8	40.8	46.0
Rep. EBIT (\$m)	40.0	54.1	59.7
Rep. NPAT (\$m)	22.6	33.9	39.2

\*Underlying unless otherwise stated


NTA (\$m) 120.1 137.5 157.5

Op CF (\$m) 43.1 68.5 65.7

### Per Share Data:

	23A	24F	25F
Norm. EPS (cps)	6.65	7.85	8.86
DPS (cps)	4.00	4.50	5.00
Div Yield	5.6%	6.3%	6.9%
NTAPS (cps)	25.4	26.5	30.3
CFPS (cps)	9.0	13.2	12.6

### Share Price Graph



Please refer to important disclosures at the end of the report (from page 3)

Wednesday, 23 August 2023

## SRG Global (SRG)

### FY23 Results

Analyst | Ian Christie

### Quick Read

No surprises in SRG's results, which met earnings guidance and expectations. The Company's outlook for ~20% EBITDA growth in FY24 reflects both inorganic (Asset Care) and organic growth. Results demonstrate a well-rounded business, with all segments contributing evenly at appropriately good margins.

### Key points

**Results summary:** Revenue of \$809M was up 26% and EBITDA of \$80.1M was up 40%, in line with guidance. NPAT before amortisation of \$2.3M and one-offs of \$6.9M was \$31.8M, and the FY23 dividend of 4.0cps was up on last year's 3.0cps payout. The EBITDA margin climbed from 8.9% to 9.9%. Segment results were well balanced, with appropriate margins generated across all divisions. The EBITDA to cash conversion of 68% was below our thinking, so net debt of \$17M was higher than our net cash expectation. Still, the balance sheet remains strong, with negligible gearing and available liquidity of \$144M.

**Outlook and forecasts:** Having won over \$1.2B contracts since the start of FY23, work in hand is now \$1.9B, two thirds of which is annuity/recurring. There is an identified pipeline of opportunities worth another \$6.5B. SRG has given FY24 EBITDA growth guidance of ~20%, implying EBITDA of ~\$96M. It suggests organic growth in the high single digits, with the balance coming from a full year contribution from recently acquired Asset Care. Our FY24 EBITDA forecast is adjusted upward by 4% to match guidance, although offset by higher depreciation and net interest costs.

Figure 1: FY23 actuals and Argonaut forecast earnings adjustments

Underlying (pre one-offs and amortisation)	FY23	FY24F			FY25F		
	Actual	Old	New	Change	Old	New	Change
Revenue (\$m)	809.0	966.0	980.0	1%	995.6	1,030.1	3%
EBITDA (\$m)	80.1	92.8	96.1	4%	96.6	101.9	5%
EBITDA margin	9.9%	9.6%	9.8%		9.7%	9.9%	
PBT (\$m)	45.8	57.1	55.3	-3%	62.7	62.8	0%

**Good balance:** SRG has executed well to date on the strategy to diversify and transform into a diversified industrial services business. The underlying EBIT(A) split between Asset Maintenance, Mining Services, and Engineering & Construction was 31%, 33% and 36% respectively in FY23. Work in hand is split 50%, 17%, and 33%, while the pipeline split is 45%, 15% and 40%.

### Valuation & recommendation

Our valuation of \$1.08 and BUY recommendation are unchanged.

## SRG Global

## Equity Research

Ian Christie

Recommendation	BUY
Current Price (\$)	0.72
Valuation (\$)	1.08

Sector	Services & Construction
Market Cap (\$m)	374.0
Date	23 August 2023

Trading Metrics	FY22A	FY23A	FY24F	FY25F
EV / EBITDA (x)		4.9	4.1	3.8
EV / EBIT (x)		7.8	6.4	5.9
P/E (x)		10.8	9.2	8.1
Dividend Yield (%)		5.6%	6.3%	6.9%

Per Share Data	FY22A	FY23A	FY24F	FY25F
Reported EPS (cps)	4.5	4.7	6.5	7.5
Adjusted EPS (cps)	5.4	6.6	7.9	8.9
Div. per share (cps)		4.0	4.5	5.0
NTA per share (cps)	29.6	25.4	26.5	30.3
CF per share (cps)	13.5	9.0	13.2	12.6

Profit and Loss (\$m)	FY22A	FY23A	FY24F	FY25F
Revenue	646.4	811.6	980.0	1,030.1
EBITDA	57.2	80.1	96.1	101.9
EBITDA Margin	8.9%	9.9%	9.8%	9.9%
Depreciation	(23.1)	(29.5)	(35.1)	(35.3)
EBIT	34.2	50.0	61.0	66.6
PBT	31.6	45.8	55.3	62.8
NPAT	24.5	31.8	40.8	46.0
Adjustments:				
Amortisation	(3.6)	(3.3)	(6.9)	(6.8)
One-Offs	(1.0)	(6.6)	-	-
Reported EBIT	29.5	40.0	54.1	59.7
Reported NPAT	20.1	22.6	33.9	39.2

Cash Flow (\$m)	FY22A	FY23A	FY24F	FY25F
Receipts	705.7	884.1	963.4	1,019.1
Payments	(646.0)	(834.1)	(874.3)	(932.9)
Other	1.4	(6.8)	(20.7)	(20.6)
Cash from Operations	61.1	43.1	68.5	65.7
Property, Plant & Equip	(18.7)	(30.3)	(26.6)	(22.8)
Payment for Subsidiary	(15.1)	(81.1)	-	-
Other	0.3	8.9	-	-
Cash From Investing	(33.6)	(102.5)	(26.6)	(22.8)
Issue of Shares	-	48.8	-	-
Net Borrowing	(3.4)	16.2	(12.1)	(39.4)
Dividends / Other	(11.1)	(17.1)	(23.4)	(26.0)
Cash From Financing	(14.5)	47.9	(35.4)	(65.3)
Net Cash Flow	13.0	(11.5)	6.4	(22.5)
Ending Cash	59.3	47.7	54.1	31.6

Balance Sheet (\$m)	FY22A	FY23A	FY24F	FY25F
Cash	59.3	47.7	54.1	31.6
Receivables	158.6	198.2	214.8	225.8
Inventory	18.7	21.5	30.3	31.8
Other	5.6	4.4	4.4	4.4
Current Assets	242.3	271.8	303.6	293.6
Property, Plant & Equip	104.3	119.0	122.9	122.6
Intangibles	102.6	170.4	163.5	156.7
Other NC Assets	35.3	29.9	29.9	29.9
Non-Current Assets	242.3	319.3	316.3	309.2
Total Assets	484.6	591.2	619.8	602.8
Payables	155.5	151.0	181.6	190.7
Borrowings	38.8	64.7	52.6	13.3
Provisions	37.2	57.4	57.4	57.4
Other	18.5	27.6	27.2	27.2
Total Liabilities	250.0	300.7	318.8	288.6
Net Assets	234.6	290.5	301.0	314.2
Ordinary Equity	218.1	267.5	267.5	267.5
Reserves	6.9	8.0	8.0	8.0
Retained Earnings	9.5	15.0	25.5	38.7
Total Equity	234.6	290.5	301.0	314.2

Valuation	Calcs.	\$m	\$ps
<b>DCF Valuation:</b>			
Discount Rate / WACC (%)	10.0%		
PV Free Cash Flow (\$m)		637.8	
Less Net Debt / Plus Cash (\$m)		(17.0)	
Unpaid Capital (\$m)		-	
Equity Value (\$m)		620.8	1.20
<b>Earnings Capitalisation Valuation:</b>			
FY24 EBIT multiple	8.0	471.0	0.91
FY24 NPAT multiple	12.5	509.8	0.98
<b>Blended Valuation (\$/share)</b>			<b>1.08</b>

Profit and Loss (\$m)	1H22A	2H22A	1H23A	2H23A
Revenue	297.3	349.2	382.1	429.4
EBITDA	27.0	30.2	34.0	46.1
EBITDA Margin	9.1%	8.6%	8.9%	10.7%
Depreciation	(11.1)	(11.9)	(13.1)	(16.3)
EBIT	15.9	18.2	20.8	29.1
PBT	14.7	16.9	19.1	26.7
NPAT	10.6	13.8	13.6	18.2
Adjustments:				
Amortisation	(1.8)	(1.8)	(1.2)	(2.1)
One-Offs	-	(1.0)	-	(6.6)
Reported EBIT	14.1	15.4	19.7	20.4
Reported NPAT	8.8	11.3	12.4	10.1

Cash Flow (\$m)	1H22A	2H22A	1H23A	2H23A
Receipts	360.6	345.0	448.1	436.0
Payments	(325.2)	(320.8)	(400.9)	(433.2)
Other	(2.0)	3.4	(2.6)	(4.2)
Cash from Operations	33.4	27.7	44.5	(1.4)
Property, Plant & Equip	(8.6)	(10.1)	(15.9)	(14.4)
Payment for Subsidiary	-	(15.1)	(1.9)	(79.2)
Other	(0.4)	0.7	1.6	7.3
Cash From Investing	(9.0)	(24.6)	(16.2)	(86.2)
Issue of Shares	-	-	-	48.8
Net Borrowing	(6.4)	3.0	(5.3)	21.5
Dividends / Other	(4.5)	(6.7)	(6.7)	(10.4)
Cash From Financing	(10.8)	(3.7)	(12.0)	59.9
Net Cash Flow	13.5	(0.5)	16.3	(27.8)
Ending Cash	59.9	59.3	75.8	47.7

Financial Ratios	FY22A	FY23A	FY24F	FY25F
<b>Growth</b>				
Revenue growth (%)	13.1%	25.6%	21.1%	5.1%
NPAT growth (%)	52.2%	29.9%	28.4%	12.8%
Norm. EPS growth (%)	51.8%	22.7%	18.1%	12.8%
<b>Profitability Ratios</b>				
EBITDA Margin (%)	8.9%	9.9%	9.8%	9.9%
EBIT Margin (%)	5.3%	6.2%	6.2%	6.5%
PBT Margin (%)	4.9%	5.6%	5.6%	6.1%
NPAT Margin (%)	3.8%	3.9%	4.2%	4.5%
Return on Assets (%)	8.3%	10.3%	11.0%	11.7%
Return on Equity (%)	10.6%	12.1%	13.8%	15.0%
ROIC (%)	8.9%	10.7%	11.0%	12.2%
<b>Balance Sheet Ratios</b>				
Net Debt (ND) / Equity (%)	-8.8%	5.8%	-0.5%	-5.8%
ND / ND + Equity (%)	-9.6%	5.5%	-0.5%	-6.2%
Current Ratio (x)	1.2	1.2	1.2	1.2
Net Interest Cover (x)	11.6	9.6	9.5	15.9
<b>Cash Flow Ratios</b>				
Free Cash Flow Yield (%)	8.4%	-19.8%	11.2%	11.5%
Cash Conversion (x)	1.3	0.6	0.8	0.7

**RESEARCH:**

**Ian Christie** | Director, Head of Research  
+61 8 9224 6872

**John Macdonald** | Director, Metals & Mining Research  
+61 8 9224 6835

**George Ross** | Senior Analyst, Metals & Mining Research  
+61 8 9224 6840

**Ben Crooks** | Associate Analyst, Metals & Mining Research  
+61 8 9224 6869

**Pat Streater** | Associate Analyst, Metals & Mining Research  
+61 8 9224 6818

**INSTITUTIONAL SALES:**

**Chris Wippl** | Executive Director, Head of Institutional Sales  
+61 8 9224 6875

**Damian Rooney** | Director, Institutional Sales Trader  
+61 8 9224 6862

**Josh Welch** | Institutional Research Sales  
+61 8 9224 6868

**George Ogilvie** | Institutional Research Sales  
+61 8 9224 6871

**Matt Middlemas** | Associate, Institutional Sales  
+61 8 9224 6803

**John Santul** | Consultant, Institutional Sales & Research  
+61 8 9224 6859

**CORPORATE AND PRIVATE CLIENT SALES:**

**Glen Colgan** | Executive Director, Desk Manager  
+61 8 9224 6874

**Kevin Johnson** | Executive Director, Corporate Stockbroking  
+61 8 9224 6880

**Ben Willoughby** | Senior Dealer, Corporate Stockbroking  
+61 8 9224 6876

**David Keogh** | Senior Dealer, Corporate Stockbroking  
+61 8 9224 6852

**Geoff Barnesby-Johnson** | Senior Dealer, Corporate Stockbroking  
+61 8 9224 6854

**Rob Healy** | Dealer, Private Clients  
+61 8 9224 6873

**James Massey** | Dealer, Corporate Stockbroking  
+61 8 9224 6849

**Cameron Prunster** | Dealer, Private Clients  
+61 8 9224 6853

**Harry Massey** | Dealer, Private Clients  
+61 8 9224 6829

**Jake Solomon** | Dealer, Private Clients  
+61 8 9224 6855

**Matej Mandic** | Dealer, Private Clients  
+61 8 9224 6887

**Amanda Fu** | Provisional Provider, Private Clients  
+61 8 9224 6805

**Information Disclosure**

Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst's personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

**For U.S. persons only**

This research report is a product of Argonaut Securities Pty Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Argonaut Securities Pty Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Argonaut Securities Pty Limited has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**General Disclosure and Disclaimer**

This research has been prepared by Argonaut Securities Pty Limited (ABN 72 108 330 650) ("ASPL") for the use of the clients of ASPL and other related bodies corporate (the "Argonaut Group") and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this report in any way. ASPL is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and ASPL has made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Argonaut Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)' personal views at the time of writing. No member of the Argonaut Group or its respective employees, agents or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Argonaut Group and/or its associates, including ASPL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Argonaut Group and/or its associates, including ASPL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.

There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on ASPL's overall revenues.

**Copyright**

© 2023. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Argonaut Securities Pty Limited. Argonaut Securities Pty Limited specifically prohibits the redistribution of this document, via the internet or otherwise, and accepts no liability whatsoever for the actions of third parties in this respect.